Advantar Labs, a GLP and GMP compliant contract laboratory provider of analytical and formulation development services to pharmaceutical, biotech and medical device companies, announces a non-exclusive strategic alliance with DavosPharma, a leading provider of chemistry and pharmaceutical development management solutions to emerging biotech and multi-national pharmaceutical companies.
Advantar will partner with DavosPharma to provide US based biotech and pharmaceutical clientele with comprehensive development, consultancy and program management support for pre-clinical and clinical trial materials as well as approved drugs and devices. Collaborative offerings include, but are not limited to custom synthesis for API's and advanced intermediates, formulation development, cGMP drug manufacturing, investigational and compatibility studies, method development and validation projects, stability studies and regulatory support.
Rich Kenley, PhD, CEO of Advantar Labs said “The alliance with DavosPharma enables our mutual clients to rapidly and confidently place their program with dedicated teams of experts to manage.” “For time critical studies, we are able to utilize DavosPharma's infrastructure and broad network to provide more options and overall guidance to customers for their development needs than previously before. This accomplishment puts our lab well ahead of many competing CRO's with in-house project management, because they often lack specific area expertise or comprehensive tracking tools.”
Giff Marzoni, PhD, VP of Global API development at DavosPharma said “The Advantar team has a tremendous breadth of analytical and formulation development experience that we leverage for our customers.” “Finding the right partner with the compliance, analytical resources and communication we need, is no easy feat. However, Rich and his team simply make it very easy to work with and get the job done right. They share our corporate vision in providing great science and exceptional support for every programme awarded.”
Davos Chemical is a highly respected, privately owned company that specializes in outsourcing and commercial development of API custom synthesis and final dosage form manufacturing. Its focus is to deliver custom intermediates, API's, pharmaceutical and process development strategies to global customers in the pharmaceutical and life science industries.